Volume | 1,034,629 |
|
|||||
News | - | ||||||
Day High | 24.76 | Low High |
|||||
Day Low | 23.49 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Avidity Biosciences Inc | RNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
24.01 | 23.49 | 24.76 | 24.36 | 23.83 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
11,484 | 1,034,629 | US$ 24.15 | US$ 24,985,793 | - | 4.825 - 27.66 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:20:00 | formt | 576 | US$ 24.36 | USD |
Avidity Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.94B | 79.72M | - | 9.56M | -212.22M | -2.66 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Avidity Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RNA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 22.89 | 26.02 | 22.24 | 24.05 | 911,668 | 1.47 | 6.42% |
1 Month | 25.55 | 27.66 | 21.56 | 24.59 | 952,191 | -1.19 | -4.66% |
3 Months | 12.03 | 27.66 | 11.23 | 20.92 | 1,167,392 | 12.33 | 102.49% |
6 Months | 5.11 | 27.66 | 4.825 | 13.64 | 1,286,729 | 19.25 | 376.71% |
1 Year | 16.87 | 27.66 | 4.825 | 12.01 | 1,146,401 | 7.49 | 44.40% |
3 Years | 22.90 | 29.59 | 4.825 | 15.39 | 785,556 | 1.46 | 6.38% |
5 Years | 26.50 | 37.46 | 4.825 | 16.43 | 665,952 | -2.14 | -8.08% |
Avidity Biosciences Description
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease. |